Lilly to Participate in Goldman Sachs Global Healthcare Conference

INDIANAPOLIS, June 9, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Goldman Sachs 35th Annual Global Healthcare Conference on Wednesday, June 11th, 2014. David Ricks, Lilly senior vice president and president of Lilly Bio-Medicines, will participate in a fireside chat at 1:40 p.m. EDT.

A live audio webcast will be available on the Webcasts & Presentations section of Lilly's Investor website at http://investor.lilly.com/events.cfm. Subsequently, a replay of the fireside chat with Mr. Ricks will be available on this same website for approximately 30 days.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels. F-LLY

Refer to: 

(317) 276-5795 – Mark Taylor (Media)


(317) 655-6874 – Philip Johnson (Investors)

 

Eli Lilly and Company logo.

 

http://photos.prnewswire.com/prnh/20031219/LLYLOGO  

 

SOURCE Eli Lilly and Company

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.